Japan Infusion Therapy Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034)

The Japan infusion therapy market was valued at USD 3.41 Billion in 2024 and is expected to grow at a CAGR of 6.40%, reaching USD 6.34 Billion by 2034 . The market growth is driven by the rising chronic disease prevalence and increasing demand for home healthcare, coupled with regulatory approvals for advanced infusion devices across the region.

Key Trends and Insights

• During the historical period, the antibiotic/antiviral segment held the largest share by therapy type, accounting for 26% of revenue.
• By product, infusion pumps are expected to lead the market in the forecast period.
• Cancer is poised to lead the market share by indication in the forecast period.

Market Size and Forecast

• Market Size (2024): USD 3.41 Billion
• Projected Market Size (2034): USD 6.34 Billion
• CAGR (2025-2034): 6.40%

Japan Infusion Therapy Market Overview

The market is witnessing steady growth, driven by an aging population and increasing prevalence of chronic diseases. Rising demand for home healthcare solutions and advanced infusion devices is encouraging hospitals and healthcare providers to adopt more efficient, patient-centric therapies. Additionally, technological innovations in infusion pumps and drug delivery systems are improving treatment accuracy and patient safety. Supportive government initiatives and growing awareness about the benefits of infusion therapy are further propelling market expansion, positioning Japan as a key region for infusion therapy adoption in the Asia-Pacific healthcare sector. The market is expected to grow at a CAGR of 6.40% during the forecast period of 2025-2034 and attain a market value of USD 6.34 Billion by 2034 .

Japan Infusion Therapy Market Growth Drivers

Regulatory Approvals and Technological Innovations Boost Market Growth

Rising demand for home healthcare solutions and growing chronic disease prevalence are key drivers of the market. For instance, in July 2024, KORU Medical Systems received regulatory clearance in Japan for its FreedomEdge® Infusion System, enabling delivery of therapies like Subcutaneous Immunoglobulin (SCIg) and treatments for rare diseases directly to patients’ homes. The portable and user-friendly system enhances patient convenience and safety, promoting wider adoption of home infusion therapies. This development is expected to accelerate market growth throughout the forecast period.

Japan Infusion Therapy Market Trends

The market is driven by regulatory approvals and innovative oncology treatments.

Expansion of Intravenous Oncology Therapies to Boost Market Growth

The launch of LUNSUMIO® (mosunetuzumab) in Japan for relapsed or refractory follicular lymphoma demonstrates a growing focus on intravenous oncology treatments. Fixed-duration infusion therapies reduce patient burden and improve adherence, driving adoption in hospitals and specialty clinics. Rising cancer prevalence and demand for advanced infusion solutions are encouraging healthcare providers to integrate these therapies, supporting market growth. Innovations in oncology infusion are poised to expand the intravenous segment, contributing significantly to the overall infusion therapy market during the forecast period.

Oncology Infusion Therapy Launches Driving Japan Infusion Therapy Market Demand

Growing demand for effective cancer treatments and technological innovations in drug delivery are major market trends. For instance, in May 2024, Nippon Shinyaku launched Vyxeos® Combination for I.V. Injection for high-risk acute myeloid leukemia, approved by Japan’s Ministry of Health in March 2024. The liposomal formulation enables controlled drug release, improving efficacy and reducing toxicity. Such advancements in intravenous oncology therapies are expected to drive hospital and clinic adoption, expanding the infusion therapy segment and contributing to significant market development during the forecast period.

Japan Infusion Therapy Market Share

Antibiotic/Antiviral Segment to Lead the Market by Therapy Type

The antibiotic/antiviral segment held the largest share of Japan’s infusion therapy market, accounting for 26% of total revenue. This segment is likely to maintain its dominance due to the high prevalence of infectious diseases and growing demand for effective intravenous treatments. Hospitals and clinics prioritize the timely administration of these therapies, ensuring rapid patient recovery. Continuous development of novel antibiotics and antiviral formulations, along with increasing awareness of infection control, further supports this segment’s leading role in market growth during the forecast period.

Leading Players in the Japan Infusion Therapy Market

The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

B. Braun SE

Founded in 1839, B. Braun SE is headquartered in Melsungen, Germany. It’s a Japan leader in medical devices and pharmaceuticals. Its broad product portfolio includes infusion therapy (infusion pumps, solutions, IV access), surgery and orthopedics, anaesthesia care, extracorporeal blood treatment, wound management, and hospital consumables. The company operates through divisions such as Hospital Care, Aesculap (surgical instruments), Avitum (dialysis), supplying hospitals, clinics, and home care.

Medtronic plc

Founded in 1949, Medtronic plc is a medical technology company headquartered in Dublin, Ireland, with operational headquarters in the United States. It develops and commercializes device-based therapies, including cardiovascular and vascular systems (pacemakers, defibrillators, stents), neuroscience (spinal stimulators, brain modulation), medical-surgical devices (surgical tools, robotics), and diabetes care. Medtronic serves hospitals, physicians, and integrated healthcare systems worldwide.

Becton, Dickinson and Company (BD)

Founded in 1897, Becton, Dickinson and Company (BD) is headquartered in Franklin Lakes, New Jersey, USA. BD is a major player in medical technology and devices, offering products across three divisions: BD Medical, BD Life Sciences, and BD Interventional. Its portfolio includes infusion systems (large volume and syringe pumps, infusion sets), drug delivery devices, diagnostics, and safety-engineered medical equipment. BD serves hospitals, outpatient care, and home health markets Japanly.

ICU Medical

Established in 1984, ICU Medical is headquartered in San Clemente, California, USA. It specializes in infusion therapy and related critical care products. Its offerings include IV smart pumps, ambulatory and large-volume infusion pumps, IV solutions and sets, needle-free connectors, closed system drug handling systems, anesthesia products, patient monitoring, and respiratory and temperature management systems. ICU supplies acute care hospitals, clinics, and alternative care sites.

Other key players in the market include Baxter AG, Terumo Medical Corporation, Fresenius Kabi, and Cardinal Health.

Japan Infusion Therapy Market Segmentation   

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product

• Infusion Pumps
• Ambulatory Infusion Pumps
• Stationary Infusion Pumps
• Syringe Infusion Pumps
• Disposable Pumps
• Large Volume Pumps
• Elastomeric Pumps
• Infusion Sets
• Accessories

Market Breakup by Indication

• Cancer
• Gastrointestinal Disorders
• Congestive Heart Failure
• Rheumatoid Arthritis
• Hemophilia
• Immune Deficiencies
• Others

Market Breakup by Therapy Type

• Antibiotic/Antiviral
• Anti-Coagulation
• Anti-Emetics
• Blood Component Stimulating Factor
• Chemotherapy
• Nutrition
• Hydration
• Pain Management
• Others

Market Breakup by End User

• Hospitals and Clinics
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings
• Others

Key Questions Answered in the Japan Infusion Therapy Market 

• What was the Japan infusion therapy market value in 2024?
• What is the Japan infusion therapy market forecast outlook for 2025-2034?
• What is the market breakup based on product?
• What is the market breakup based on the indication?
• What is the market breakup based on therapy type?
• What is the market breakup based on the end user?
• What are the major factors aiding the Japan infusion therapy market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Japan infusion therapy market trends?
• Which product will lead the market segment?
• Which indication will lead the market segment?
• Which therapy type will lead the market segment?
• Which end user will lead the market segment?
• Who are the key players involved in the Japan infusion therapy market?
• What are the current unmet needs and challenges in the market?

This product will be delivered within 3-5 business days.